Document is current

Article History

Received: 14 April 2023

Accepted: 14 August 2023

First Online: 20 August 2023

Declarations

:

: All the animal experiments and procedures were received prior approval from the Animal Research Ethics Sub-Committees of the City University of Hong Kong and the Department of Health of the Government of the Hong Kong Special Administrative Region.

: All authors of the manuscript have agreed to publish this article.

: JCS is listed as an inventor on a patent (WO2015188288A1) entitled “Specific modulators of connexin hemichannels” related to the development of the small organic molecule D4. JCS is also a named inventor on a patent (CL2017002254A1) entitled “Selective hemichannel inhibitors formed by connexins for the treatment of epilepsy” related to the therapeutic potential of D4 in epilepsy. CGL and HL are co-inventors on a patent entitled “一种半通道抑制剂在药学上的应用 / Pharmaceutical application of a hemichannel inhibitor” covering the therapeutic application of D4 as an antidepressant using some of the results described in this manuscript (CN202211496351.7; filed on November 25, 2022). This patent is “preliminarily approved” by the China National Intellectual Property Administration (January 16, 2023). Other authors declare no conflicts of interest.